Sovremennyy vzglyad na problemu skrininga raka predstatel'noy zhelezy


Cite item

Full Text

References

  1. De Koning H. J., Essink-Bot M. L., Schroder F. H. Screening for prostate cancer. In: Prostate cancer. Clinical and scientific aspects-bridging the gap. London: Imperial College Press; 2003; 683-708.
  2. Available at URL: http://www.urologyhealth.org/adult/ index.cfm?cat = 09&topic = 250. Accessed February 1, 2007.
  3. De Koning H. J., Auvinen A., Berenguer Sanchez A. et al. Large-scale randomized prostate cancer screening trials: program performances in the European Randomized Screening for Prostate Cancer trial and the Prostate, Lung, Colorectal and Ovary Cancer Trial. Int. J. Cancer 2002; 97: 237-244.
  4. Roobol M. J., Schroder F. H. European Randomized Study of Screening for Prostate Cancer: achievements and presentatijn. Br. J. Urol. Int. 2003; 92 (suppl. 2): 117-122.
  5. Albertsen P. C., Hanley J. A., Gleason D. F., Barry M. J. Competing risk analysis of men aged 55 to 74 years at diagnosis managed conservatively for clinically localized prostate cancer. J. A. M. A. 1998; 280: 975-980.
  6. Steyerberg E. W., Roobol M. J., Kattan M. W. et al. Prediction of indolent prostate cancer: validation and updating of a prognostic nomogram. J. Urol. (Baltimore) 2007; 177: 107-112; discus.: 112.
  7. Albertsen P. C., Hanley J. A., Barrows G. H. et al, Prostate cancer and the Will Rogers phenomenon. J. Natl. Cancer Inst. 2005; 97: 1248-1253.
  8. Whitmore W. F. J. Localised prostate cancer: management and detection issues. Lancet 1994; 343: 1263-1267.
  9. McGregor M., Hanley J. A., Boivin J. F., McLean R. G. Screening for prostate cancer: estimating the magnitude of overdetection. Can. Med. Assoc. J. 1998; 159: 13687-13727.
  10. Miller D. C., Gruber S. B., Hollenbeck B. K. et al. Incidence of initial local therapy among men with lower-risk prostate cancer in the United States. J. Natl. Cancer Inst. 2006; 98: 1134-1141.
  11. Stamey Т. А., Caldwell M., McNeal J. E. et al. The prostate specific antigen era in the United States is over for prostate cancer: what happened in the last 20 years? J. Urol. (Baltimore) 2004; 172: 1297-1301.
  12. Brant L. J., Sheng S. L. Screening for prostate cancer by using random-effects models. Royal Statist. Soc. 2003; 166: 51-62.
  13. Auvinen A., Maattanen L., Stenman U. H. et al. Lead-time in prostate cancer screening (Finland). Cancer Causes Control. 2002; 13: 279-285.
  14. Melia J. Part 1: The burden of prostate cancer, its natural history, information on the outcome of screening and estimates of ad hoc screening with particular reference to England and Wales. Br. J. Urol. Int. 2005; 95 (suppl. 3): 4-15.
  15. Stenman U. H., Hakama М., Knekt P. et al. Serum concentrations of prostate specific antigen and its complex with alpha 1-antichymotrypsin before diagnosis of prostate cancer. Lancet 1994; 344: 1594-1598.
  16. Gann P. H., Hennekens C. H., Stampfer M. J. A prospective evaluation of plasma prostate-specific antigen for detection of prostatic cancer. J. A. M. A. 1995; 273: 289-294.
  17. Stephenson R. A. Prostate cancer trends in the era of prostate specific antigen: an update of incidence, mortality and clinical factors from the SEEP database. Urol. Clin. N. Am. 2002; 29: 173-178.
  18. Roddam A. W., Hamdy F. C., Allen N. E., Price C. P. The impact of reducing the prostate-specific antigen threshold and including isoform reflex tests on the performance characteristics of a prostate-cancer detection programme. Br. J. Urol. Int. 2007; 100: 514-517; 2003; 62: 19-35.
  19. Fossa S. D., Eri L. M., Skovlund E. Т. et al. No randomised trial of prostate-cancer screening in Norway. Lancet Oncol. 2001; 2: 741-745; discus. 746-794.
  20. Adolfsson J., Tribukait B., Levitt S. The 20-yr outcome in patients with well- or moderately differentiated clinically localized prostate cancer diagnosed in the pre-PSA era: the prognostic value of tumor ploidy and comorbidity. Eur. J. Urol. 2007; 52: 1028-1035.
  21. The International Prostate Screening Trial Evaluation Group. Rationale for randomised trials of prostate cancer screening. Eur. J. Cancer 1999; 35: 262-271.
  22. Bartsch G., Horninger W., KlockerH. et al. Prostate cancer mortality after introduction of prostate-specific antigen mass screening in the Federal State of Tyrol, Austria. Urology 2001; 58: 417-424.
  23. Carter H. B. Rationale for earlier and less frequent prostate cancer screening. Urology 2001; 58: 639-641.
  24. Lu-Yao G., Albertsen P. C., Stanford J. L. et al. Natural experiment examining impact of aggressive screening and treatment on prostate cancer mortality in two fixed cohorts from Seattle area and Connecticut. Br. Med. J. 2002; 325: 740-743.
  25. Labrie F., Candas В., Dupont A. et al. Screening decreases prostate cancer death: first analysis of the 1988 Quebec prospective randomized controlled trial. Prostate 1999; 38: 83-91.
  26. Alexander F. E., Prescott R. J. Reply to Fabrie et al. Results of the mortality analysis of the Quebec randomised/controlled trial (RCT). Prostate 1999; 40: 135-137.
  27. Boer R., Schroder F. H. Quebec randomized controlled trial on prostate cancer screening shows no evidence for mortality reduction. Prostate 1999; 40: 130-134.
  28. Melia J., Moss S., Johns L. Rates of prostate-specific antigen testing in general practice in England and Wales in asymptomatic and symptomatic patients: a cross-sectional study. Br. J. Urol. Int. 2004; 94: 51-56.
  29. Vis A. N., Hoedemaeker R. F., Roobol-Bouts M. et al. Tumor characteristics in screening for prostate cancer with and without rectal examination as an initial screening test at low PSA (0,0- 3,9 ng/ml). Prostate 2001; 47: 252-261.
  30. Labrie F., Candas В., Dupont A. et al. Screening decreases prostate cancer death: first analysis of the 1988 Quebec prospective randomized controlled trial. Prostate 1999; 38: 83-91.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies